Effect of hepatitis C virus and its treatment on survival

Hepatology

Volumn 50, Issue 2, 2009, Pages 387-392

  Butt, Adeel A ^a,b,c   Wang, Xiaoqiang ^b   Moore, Charity G ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Center for Health Equity Research and Promotion   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; PEGINTERFERON ALPHA; RIBAVIRIN; ANTIVIRUS AGENT;

ADULT; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HAZARD RATIO; HEPATITIS C; HUMAN; MALE; MORTALITY; PREDICTION; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL; TREATMENT DURATION; TREATMENT OUTCOME; VETERAN; CASE CONTROL STUDY; MIDDLE AGED; UNITED STATES;

ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; FEMALE; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; UNITED STATES; VETERANS;

EID: 68949181545     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.23000     Document Type: Article

References (29)

1. Butt AA. Hepatitis C virus infection: the new global epidemic. Expert Rev Anti Infect Ther 2005;3:241-249. (Pubitemid 40598003)
2. El Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. HEPATOLOGY 2002;36(5 Suppl 1):S74-S83.
3. El Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004;127(5 Suppl 1):S27-S34.
4. Bonino F. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 1998 May 23;351:1535-1539. (Pubitemid 28230887)
5. Nishiguchi S, Shiomi S, Nakatani S, Takeda T, Fukuda K, Tamori A, et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 2001;357:196-197. (Pubitemid 32108094)
6. Papatheodoridis GV, Papadimitropoulos VC, Hadziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Aliment Pharmacol Ther 2001;15:689-698. (Pubitemid 32385874)
7. Guiltinan AM, Kaidarova Z, Custer B, Orland J, Strollo A, Cyrus S, et al. Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors. Am J Epidemiol 2008;167:743-750.
8. Neal KR, Ramsay S, Thomson BJ, Irving WL. Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study. Gut 2007;56:1098-1104.
9. Seeff LB, Miller RN, Rabkin CS, Buskell-Bales Z, Straley-Eason KD, Smoak BL, et al. 45-Year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000;132:105-111. (Pubitemid 30044176)
10. Harris HE, Ramsay ME, Andrews N, Eldridge KP. Clinical course of hepatitis C virus during the first decade of infection: cohort study. BMJ 2002;324:450-453. (Pubitemid 34169458)
11. Backus LI, Phillips BR, Boothroyd DB, Mole LA, Burgess J, Rigsby MO, et al. Effects of hepatitis C virus coinfection on survival in veterans with HIV treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2005;39:613-619. (Pubitemid 41098479)
12. Pineda JA, Romero-Gomez M, Diaz-Garcia F, Giron-Gonzalez JA, Montero JL, Torre-Cisneros J, et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. HEPATOLOGY 2005;41:779-789. (Pubitemid 40462940)
13. Batty DS Jr, Swanson SJ, Kirk AD, Ko CW, Agodoa LY, Abbott KC. Hepatitis C virus seropositivity at the time of renal transplantation in the United States: associated factors and patient survival. Am J Transplant 2001;1:179-184.
14. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122:889-896. (Pubitemid 34267271)
15. Espinosa M, Martin-Malo A, Alvarez de Lara MA, Aljama P. Risk of death and liver cirrhosis in anti-HCV-positive long-term haemodialysis patients. Nephrol Dial Transplant 2001;16:1669-1674. (Pubitemid 32750462)
16. Butt AA, Skanderson M, McGinnis KA, Ahuja TS, Bryce C, Barnato AE, et al. Impact of hepatitis C virus infection and other comorbidities on survival in patients on dialysis. J Viral Hepat 2007;14:688-696. (Pubitemid 47414929)
17. Campos NG, Salomon JA, Servoss JC, Nunes DP, Samet JH, Freedberg KA, et al. Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV. Am J Med 2007;120:272-279. (Pubitemid 46341166)
18. Manns MP, McHutchinson JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965. (Pubitemid 32913521)
19. Zeuzem S, Feinman SV, Rasenack J, Heathcote J, Lai MY, Gane E, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-1672.
20. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
21. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-355.
22. Butt AA, Justice AC, Skanderson M, Rigsby M, Good CB, Kwoh CK. Rate and predictors of treatment prescription for hepatitis C. Gut 2007;56:385-389.
23. Butt AA, Khan UA, McGinnis KA, Skanderson M, Kwoh CK. Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veterans. J Viral Hepat2007;14:890-896.
24. Butt AA, Justice AC, Skanderson M, Good CB, Kwoh CK. Rates and predictors of HCV treatment in HCV-HIV coinfected persons. Aliment Pharmacol Ther 2006;24:585-591.
25. An Introduction to Survival Analysis Using Stata. 2nd ed. College Station, TX: Stata Press; 2008.
26. Butt AA, Khan UA, Skanderson M. Comorbidities and their impact on mortality in HCV and HCV-HIV co-infected persons on dialysis. J Clin Gastroenterol 2008;42:1054-1059.
27. Cawthorne CH, Rudat KR, Burton MS, Brown KE, Luxon BA, Janney CG, et al. Limited success of HCV antiviral therapy in United States veterans. Am J Gastroenterol 2002;97:149-155.
28. Nguyen HA, Miller AI, Dieperink E, Willenbring ML, Tetrick LL, Durfee JM, et al. Spectrum of disease in U.S. veteran patients with hepatitis C. Am J Gastroenterol 2002;97:1813-1820. (Pubitemid 34761412)
29. Cheung RC. Epidemiology of hepatitis C virus infection in American veterans. Am J Gastroenterol 2000;95:740-747. (Pubitemid 30123913)